Objective To investigate the relationship between syndecan-1 protein and malignant phenotypes of hepatocellular carcinoma (HCC).
Methods forty-seven formalin-fixed sections were obtained. The syndecan-1 was measured with immunohistochemistry assay (ABC method).
Results Among 47 HCC tissues, 28 (59.6%) show negative staining, the syndecan-1 negative rate in HCC with poor differentiation was higher than those with good differentiation (78.3% vs 41.7%, Ｐ＜0.05), and negative rate in large HCC was higher than in small HCC (81.0% vs 42.3%, Ｐ＜0.01), and negative rate in HCC with the presence of tumor-cells in blood was greater than in those without tumor-cells in blood (84.2% vs 42.9%, P＜0.01). No correlation was found between syndecan-1 expression and serum AFP level and Child class. Conclusion Syndecan-1 expression is correlated with the growth, differentiation, invasiveness, metastasis and progression of HCC. It is possible that syndecan-1 is a negative regulator of these malignant phenotypes of HCC, can be regarded as suppressive gene.
Citation：
WANG Xuehao,CHENG Feng,QIAN Jianmin,et al.. CORRELATION BETWEEN SYNDECAN-1 PROTEIN EXPRESSION AND MALIGNANT PHENOTYPES OF HEPATOCELLULAR CARCINOMA. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2001, 8(4): 239-241. doi:
Copy
Copyright © the editorial department of CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY of West China Medical Publisher. All rights reserved
| 1. |
Inki P, Joensuu H, Grenman R, et al. Association between syndecan1 expression and clinical outcome in squamous cell carcinoma of the head and neck 〔Ｊ〕. Br J Cancer, 1994; 70(2)∶319.
|
| 2. |
Bernfield M, Kokenyesi P, Kato M, et al. Biology of the syndecans 〔Ｊ〕. Ann Rev Biochem, 1992; 8∶365.
|
| 3. |
Roskams T, Moshage H, De Vos R, et al. Heparan sulfate proteoglycan expression in normal human liver 〔Ｊ〕. Hepatology, 1995; 21(4)∶950.
|
| 4. |
Roskams T, De Vos R, David G, et al. Heparan sulphate proteoglycan expression in human primary liver tumors 〔Ｊ〕. J Pathol, 1998; 185(3)∶290.
|
| 5. |
Matsumoto A, Ono M, Fujimoto Y, et al. Reduced expression of syndecan1 in human hepatocellular carcinoma with high metastatic potential 〔Ｊ〕. Int J Cancer, 1997; 74(5)∶482.
|
| 6. |
Mali M, Andfolk H, Miettinen HM, et al. Suppression of tumor cell growth by syndecan1 ectodomain 〔Ｊ〕. J Biol Chem, 1994; 269(45)∶27795.
|
| 7. |
KumarSingh S, Jacobs W, Dhaene K, et al. Syndecan1 expression in maligant mesothlioma: correlation with differentiation, wtl expression, and clinical outcome 〔Ｊ〕. J Pathol, 1998; 186(3)∶300.
|
| 8. |
Izumi R, Shimizu K, Li T, et al. Prognostic factors of hepatocellular carcinoma in patients undergoing hepatic resection 〔Ｊ〕. Gastroenterology, 1994; 106(3)∶720.
|
- 1. Inki P, Joensuu H, Grenman R, et al. Association between syndecan1 expression and clinical outcome in squamous cell carcinoma of the head and neck 〔Ｊ〕. Br J Cancer, 1994; 70(2)∶319.
- 2. Bernfield M, Kokenyesi P, Kato M, et al. Biology of the syndecans 〔Ｊ〕. Ann Rev Biochem, 1992; 8∶365.
- 3. Roskams T, Moshage H, De Vos R, et al. Heparan sulfate proteoglycan expression in normal human liver 〔Ｊ〕. Hepatology, 1995; 21(4)∶950.
- 4. Roskams T, De Vos R, David G, et al. Heparan sulphate proteoglycan expression in human primary liver tumors 〔Ｊ〕. J Pathol, 1998; 185(3)∶290.
- 5. Matsumoto A, Ono M, Fujimoto Y, et al. Reduced expression of syndecan1 in human hepatocellular carcinoma with high metastatic potential 〔Ｊ〕. Int J Cancer, 1997; 74(5)∶482.
- 6. Mali M, Andfolk H, Miettinen HM, et al. Suppression of tumor cell growth by syndecan1 ectodomain 〔Ｊ〕. J Biol Chem, 1994; 269(45)∶27795.
- 7. KumarSingh S, Jacobs W, Dhaene K, et al. Syndecan1 expression in maligant mesothlioma: correlation with differentiation, wtl expression, and clinical outcome 〔Ｊ〕. J Pathol, 1998; 186(3)∶300.
- 8. Izumi R, Shimizu K, Li T, et al. Prognostic factors of hepatocellular carcinoma in patients undergoing hepatic resection 〔Ｊ〕. Gastroenterology, 1994; 106(3)∶720.
